Browse Studies — Arctuva

Phase 1

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the …

Malignancy, HematologicNeoplasms, HematologicNeoplasms, Hematopoietic+8 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06904066

Phase 2

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications fo…

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute

Estimated

~$10 – $7,500

Guenther KoehneNCT05565105

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more

Estimated

~$10 – $8,750

Sumitomo Pharma America, Inc.NCT04988555